ASCO 2023 roundup: Blood tests, drugs and exercise
Cancer Research UK - Science Update,
For cancer researchers with news to share, there’s no place like ASCO. The American Society for Clinical Oncology’s Annual…
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Overview of attention for article published in Journal of Clinical Oncology, May 2023
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (96th percentile)
-
High Attention Score compared to outputs of the same age and source (93rd percentile)
Readers on
- mendeley
- 23 Mendeley